The ENDEAVOUR lung cancer program, a three-year initiative designed to advance lung cancer research and care by connecting early-career oncologists in Europe with internationally renowned experts in ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval our partner Jazz Pharmaceuticals received from the U.S. Food and Drug Administration in 2024 for Ziihera® ...

UK pharma major AstraZeneca (LSE: AZN) is set to present data from more than 80 studies at the 2025 American Society of ...

The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...

IHH Healthcare’s indirect subsidiary, NTK, has filed an application with the Tokyo District Court to increase its ongoing ...

Malaysia's IHH Healthcare has significantly increased its damage claim against Japan's Daiichi Sankyo in Tokyo District Court ...

IHH Healthcare said on Tuesday its unit has filed a petition in a Tokyo court to revise damages sought from Japan's Daiichi ...

"Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial" was originally created and published by ...

Tess Stynes - profile from The Wall Street Journal. News, articles, biography and photos.